Affiliation:
1. Department of Laboratory Medicine Karolinska Institute Stockholm Sweden
2. Doping Control Laboratory, Clinical Pharmacology, Karolinska University Laboratory Karolinska University Hospital Stockholm Sweden
3. Drugs of Abuse Laboratory, Clinical Pharmacology, Karolinska University Laboratory Karolinska University Hospital Stockholm Sweden
Abstract
AbstractSelective androgen receptor modulators (SARMs) are prohibited by the World Anti‐Doping Agency (WADA) since 2008. Similarly, to anabolic androgenic steroids (AAS), SARMs are detrimental to health not only in athletes but also in the general population. However, studies of the occurrence of SARMs outside of sport are scarce. Swedish healthcare samples from the Drugs of Abuse Laboratory at Karolinska were analyzed using WADA‐accredited screening methods at the Doping Control Laboratory in Stockholm to estimate the frequency of SARM use outside of the WADA laboratories. Twenty (4%) of the male urine samples (n = 542) were positive for SARMs, whereas none of the analyzed female samples (n = 100) contained any SARMs. The top three SARMs found were LGD‐4033 followed by RAD140 and ostarine. Two or more SARMs were found in >50% of the SARM‐positive samples. AASs were identified in 40% of samples containing SARMs. A difference between genders was observed where 34% male and 7% female samples contained AAS. Many samples displayed testosterone/epitestosterone values indicative of testosterone intake, without presence of other AAS, and hence, there is a risk that these samples are being falsely reported as negative. Our results indicate that SARM use might be a concern outside of sport. Subsequently, in addition to AAS, the healthcare system should also be informed about SARM abuse and the associated adverse side effects.
Funder
Stockholms Läns Landsting
Subject
Spectroscopy,Pharmaceutical Science,Environmental Chemistry,Analytical Chemistry